高级检索
当前位置: 首页 > 详情页

miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 2, Dept Gen Surg, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Gen Surg, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Hosp 4, Med Res Ctr, Shijiazhuang, Hebei, Peoples R China [4]Hebei Med Univ, Hosp 4, Dept Intervent Radiol, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: miR-124 ZEB2 epithelial-mesenchymal transition Triple-negative breast cancer Invasion Metastasis

摘要:
Background: Triple-negative breast cancer (TNBC) is highly invasive and aggressive and lacks specific molecular targets to improve the prognosis. MicroRNAs (miRNAs) serve a role in promoting and suppressing tumors in various types of malignant cancer, including TNBC. However, the regulatory mechanism of miR-124 in TNBC has still remains unclear. Methods: Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-124. Cell viability was analyzed with CCK-8 assay. Cell colony formation ability was detected with colony formation assay. Cell invasion was measured with transwell assay. Dual luciferase reporter assay was conducted to verify whether ZEB2 is a target gene of miR-124. The mRNA and protein expression levels of ZEB2 and EMT markers were detected by quantitative real time PCR and western blot, respectively. Results: Our results showed that miR-124 was down-regulated in TNBC tissues and cells. Overexpression of miR-124 inhibited the proliferation, metastasis and epithelial-mesenchymal transition (EMT) of TNBC cells. Furthermore, ZEB2 3'UTR was considered to be a direct target of miR-124 with luciferase reporter assay. Rescue experiments confirmed that EMT was regulated by miR-124 via suppression of ZEB2. Conclusion: miR-124 suppresses EMT and metastasis via ZEB2. Therefore, miR-124 may represent a potential therapeutic target for TNBC.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 病理学
JCR分区:
出版当年[2019]版:
Q3 PATHOLOGY
最新[2023]版:
Q2 PATHOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 2, Dept Gen Surg, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Hosp 4, Dept Gen Surg, Shijiazhuang, Hebei, Peoples R China [*1]Hebei Med Univ, Hosp 4, Breast Ctr, 12 Jiankang Rd, Shijiazhuang 050017, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号